Compare LTC Properties Inc (LTC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs BIO-TECHNE Corp — how do they compare? LTC Properties Inc trades at $42.7 (market cap $2.27B), while BIO-TECHNE Corp trades at $72.5 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 5× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.42%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and BIO-TECHNE Corp for 64 Days on average.
| LTC | TECH | |
|---|---|---|
Market Cap | $2.27B | $11.36B |
Volume | 574,171 | 5,390,331 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $72.61 |
52-Week Low | $33.98 | $43.31 |
Typical Hold Time | 88 Days | 64 Days |
Enterprise Value | $3.01B | $11.39B |
Dividend Yield | 5.42% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.63, up 1.96% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT maintains strong fundamentals with 38.93% net margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million signal aggressive growth in seniors housing properties, though the stock faces resistance near $43.
Outlook remains cautiously optimistic with a $49.67 analyst price target suggesting 16% upside potential. Key opportunities include demographic tailwinds in senior care and portfolio transformation, while risks involve rising interest rates and execution challenges in SHOP segment expansion. The 31.82% buy rating reflects balanced Wall Street sentiment amid transition phase.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
